GSK reports 8.9 billion pounds in Q3 revenue with 15% growth in specialty segment
GSK GSK Plc ADR
$47.76 -0.13%
View chart & analysis → - 1GSK recorded 8.9 billion pounds in Q3 revenue.
- 2The GSK specialty segment saw 15% growth during the quarter.
- 3GSK has conducted 18 Phase 3 clinical trials to date.
So what's the key point?
GSK's Q3 revenue was 8.9 billion pounds. The specialty segment grew by 15%, and 18 Phase 3 clinical trials were conducted.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.